Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial

Lykke Midtbøll Ørnbjerg; Mikkel Østergaard; Tonny Jensen; K Hørslev-Petersen; Kristian Stengaard-Pedersen; Peter Junker; T Ellingsen; P Ahlquist; H Lindegaard; A Linauskas; A Schlemmer; Mette Yde Dam; I Hansen; T Lottenburger; C G Ammitzbøll; A. Jørgensen; Sophine Boysen Krintel; Johnny Raun; Merete Lund Hetland; Ole Slot; Lars Kjær Nielsen; Henrik Skjødt; Ole Majgaard; Tove Lorenzen; Hans Christian Horn; Marcin Kowalski; Inger Lauge Johansen; Peter Mosborg Pedersen; Natalia Manilo; Henning Bliddal; OPERA Study Group

doi:10.1007/s10067-016-3489-1

Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial

Lykke Midtbøll Ørnbjerg, Mikkel Østergaard, Tonny Jensen, K Hørslev-Petersen, Kristian Stengaard-Pedersen, Peter Junker, T Ellingsen, P Ahlquist, H Lindegaard, A Linauskas, A Schlemmer, Mette Yde Dam, I Hansen, T Lottenburger, C G Ammitzbøll, A. Jørgensen, Sophine Boysen Krintel, Johnny Raun, Merete Lund Hetland, Ole SlotLars Kjær Nielsen, Henrik Skjødt, Ole Majgaard, Tove Lorenzen, Hans Christian Horn, Marcin Kowalski, Inger Lauge Johansen, Peter Mosborg Pedersen, Natalia Manilo, Henning Bliddal, OPERA Study Group

Institut for Klinisk Medicin

5 Citationer (Scopus)

Abstract

This study aims to investigate 1-year hand bone loss (HBL_1-year) in early rheumatoid arthritis (RA) patients treated with a methotrexate (MTX) and intra-articular triamcinolone treat-to-target strategy +/− adalimumab and to determine if HBL_6months is associated with radiographic progression after 2 years. In a clinical trial (OPERA) of 180 treatment-naive early RA patients, bone mineral density (BMD) was estimated from hand radiographs with digital X-ray radiogrammetry (DXR) at baseline, after 6 (n = 90) and 12 months (n = 70) of follow-up. Baseline and 2-year radiographs were scored according to the Sharp/van der Heijde method. Baseline characteristics and HBL_6months (0–6 months changes in DXR-BMD) were investigated as predictors of structural damage by univariate linear (∆ total Sharp/van der Heijde score (TSS) as dependent variable) and logistic (+/−radiographic progression (∆TSS >0) as dependent variable) regression analyses. Variables with p < 0.10 were included in multivariable models. In 70 patients with available HBL_1-year data, HBL_1-year was median (interquartile range (IQR)) −1.9 (−3.3; −0.26 mg/cm²) in the MTX + placebo group and −1.8 (−3.6; 0.06) mg/cm² in the MTX + adalimumab group, p = 0.98, Wilcoxon signed-rank. Increased HBL (compared to general population reference values) was found in 26/37 and 23/33 patients in the MTX + placebo and MTX + adalimumab groups, chi-squared = 0.99. In 90 patients with HBL_6months data and 2-year radiographic data, HBL_6months was independently associated with ∆TSS after 2 years (β = −0.086 (95% confidence interval = −0.15; −0.025) TSS unit/mg/cm² increase, p = 0.006) but not with presence of radiographic progression (∆TSS >0) (OR 0.96 (0.92–1.0), p = 0.10). In early RA patients treated with a methotrexate-based treat-to-target strategy, the majority of patients had increased HBL_1-year, irrespective of adalimumab; HBL_6months was independently associated with ∆TSS after 2 years.

Originalsprog	Engelsk
Tidsskrift	Clinical Rheumatology
Vol/bind	36
Udgave nummer	4
Sider (fra-til)	781-789
Antal sider	9
ISSN	0770-3198
DOI	https://doi.org/10.1007/s10067-016-3489-1
Status	Udgivet - 1 apr. 2017

Adgang til dokumentet

10.1007/s10067-016-3489-1

Citationsformater

Ørnbjerg, L. M., Østergaard, M., Jensen, T., Hørslev-Petersen, K., Stengaard-Pedersen, K., Junker, P., Ellingsen, T., Ahlquist, P., Lindegaard, H., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I., Lottenburger, T., Ammitzbøll, C. G., Jørgensen, A., Krintel, S. B., Raun, J., Hetland, M. L., ... OPERA Study Group (2017). Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial. Clinical Rheumatology, 36(4), 781-789. https://doi.org/10.1007/s10067-016-3489-1

Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial. / Ørnbjerg, Lykke Midtbøll; Østergaard, Mikkel; Jensen, Tonny et al.
I: Clinical Rheumatology, Bind 36, Nr. 4, 01.04.2017, s. 781-789.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Ørnbjerg, LM, Østergaard, M, Jensen, T, Hørslev-Petersen, K, Stengaard-Pedersen, K, Junker, P, Ellingsen, T, Ahlquist, P, Lindegaard, H, Linauskas, A, Schlemmer, A, Dam, MY, Hansen, I, Lottenburger, T, Ammitzbøll, CG, Jørgensen, A, Krintel, SB, Raun, J, Hetland, ML, Slot, O, Nielsen, LK, Skjødt, H, Majgaard, O, Lorenzen, T, Horn, HC, Kowalski, M, Johansen, IL, Pedersen, PM, Manilo, N, Bliddal, H & OPERA Study Group 2017, 'Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial', Clinical Rheumatology, bind 36, nr. 4, s. 781-789. https://doi.org/10.1007/s10067-016-3489-1

Ørnbjerg LM, Østergaard M, Jensen T, Hørslev-Petersen K, Stengaard-Pedersen K, Junker P et al. Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial. Clinical Rheumatology. 2017 apr. 1;36(4):781-789. doi: 10.1007/s10067-016-3489-1

@article{27d3a442bfde49599d4d2d55f06d7b35,

title = "Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial",

abstract = "This study aims to investigate 1-year hand bone loss (HBL1-year) in early rheumatoid arthritis (RA) patients treated with a methotrexate (MTX) and intra-articular triamcinolone treat-to-target strategy +/− adalimumab and to determine if HBL6months is associated with radiographic progression after 2 years. In a clinical trial (OPERA) of 180 treatment-naive early RA patients, bone mineral density (BMD) was estimated from hand radiographs with digital X-ray radiogrammetry (DXR) at baseline, after 6 (n = 90) and 12 months (n = 70) of follow-up. Baseline and 2-year radiographs were scored according to the Sharp/van der Heijde method. Baseline characteristics and HBL6months (0–6 months changes in DXR-BMD) were investigated as predictors of structural damage by univariate linear (∆ total Sharp/van der Heijde score (TSS) as dependent variable) and logistic (+/−radiographic progression (∆TSS >0) as dependent variable) regression analyses. Variables with p < 0.10 were included in multivariable models. In 70 patients with available HBL1-year data, HBL1-year was median (interquartile range (IQR)) −1.9 (−3.3; −0.26 mg/cm2) in the MTX + placebo group and −1.8 (−3.6; 0.06) mg/cm2 in the MTX + adalimumab group, p = 0.98, Wilcoxon signed-rank. Increased HBL (compared to general population reference values) was found in 26/37 and 23/33 patients in the MTX + placebo and MTX + adalimumab groups, chi-squared = 0.99. In 90 patients with HBL6months data and 2-year radiographic data, HBL6months was independently associated with ∆TSS after 2 years (β = −0.086 (95% confidence interval = −0.15; −0.025) TSS unit/mg/cm2 increase, p = 0.006) but not with presence of radiographic progression (∆TSS >0) (OR 0.96 (0.92–1.0), p = 0.10). In early RA patients treated with a methotrexate-based treat-to-target strategy, the majority of patients had increased HBL1-year, irrespective of adalimumab; HBL6months was independently associated with ∆TSS after 2 years.",

keywords = "Journal Article",

author = "{\O}rnbjerg, {Lykke Midtb{\o}ll} and Mikkel {\O}stergaard and Tonny Jensen and K H{\o}rslev-Petersen and Kristian Stengaard-Pedersen and Peter Junker and T Ellingsen and P Ahlquist and H Lindegaard and A Linauskas and A Schlemmer and Dam, {Mette Yde} and I Hansen and T Lottenburger and Ammitzb{\o}ll, {C G} and A. J{\o}rgensen and Krintel, {Sophine Boysen} and Johnny Raun and Hetland, {Merete Lund} and Ole Slot and Nielsen, {Lars Kj{\ae}r} and Henrik Skj{\o}dt and Ole Majgaard and Tove Lorenzen and Horn, {Hans Christian} and Marcin Kowalski and Johansen, {Inger Lauge} and Pedersen, {Peter Mosborg} and Natalia Manilo and Henning Bliddal and {OPERA Study Group}",

year = "2017",

month = apr,

day = "1",

doi = "10.1007/s10067-016-3489-1",

language = "English",

volume = "36",

pages = "781--789",

journal = "Clinical Rheumatology",

issn = "0770-3198",

publisher = "Springer",

number = "4",

}

TY - JOUR

T1 - Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial

AU - Ørnbjerg, Lykke Midtbøll

AU - Østergaard, Mikkel

AU - Jensen, Tonny

AU - Hørslev-Petersen, K

AU - Stengaard-Pedersen, Kristian

AU - Junker, Peter

AU - Ellingsen, T

AU - Ahlquist, P

AU - Lindegaard, H

AU - Linauskas, A

AU - Schlemmer, A

AU - Dam, Mette Yde

AU - Hansen, I

AU - Lottenburger, T

AU - Ammitzbøll, C G

AU - Jørgensen, A.

AU - Krintel, Sophine Boysen

AU - Raun, Johnny

AU - Hetland, Merete Lund

AU - Slot, Ole

AU - Nielsen, Lars Kjær

AU - Skjødt, Henrik

AU - Majgaard, Ole

AU - Lorenzen, Tove

AU - Horn, Hans Christian

AU - Kowalski, Marcin

AU - Johansen, Inger Lauge

AU - Pedersen, Peter Mosborg

AU - Manilo, Natalia

AU - Bliddal, Henning

AU - OPERA Study Group

PY - 2017/4/1

Y1 - 2017/4/1

N2 - This study aims to investigate 1-year hand bone loss (HBL1-year) in early rheumatoid arthritis (RA) patients treated with a methotrexate (MTX) and intra-articular triamcinolone treat-to-target strategy +/− adalimumab and to determine if HBL6months is associated with radiographic progression after 2 years. In a clinical trial (OPERA) of 180 treatment-naive early RA patients, bone mineral density (BMD) was estimated from hand radiographs with digital X-ray radiogrammetry (DXR) at baseline, after 6 (n = 90) and 12 months (n = 70) of follow-up. Baseline and 2-year radiographs were scored according to the Sharp/van der Heijde method. Baseline characteristics and HBL6months (0–6 months changes in DXR-BMD) were investigated as predictors of structural damage by univariate linear (∆ total Sharp/van der Heijde score (TSS) as dependent variable) and logistic (+/−radiographic progression (∆TSS >0) as dependent variable) regression analyses. Variables with p < 0.10 were included in multivariable models. In 70 patients with available HBL1-year data, HBL1-year was median (interquartile range (IQR)) −1.9 (−3.3; −0.26 mg/cm2) in the MTX + placebo group and −1.8 (−3.6; 0.06) mg/cm2 in the MTX + adalimumab group, p = 0.98, Wilcoxon signed-rank. Increased HBL (compared to general population reference values) was found in 26/37 and 23/33 patients in the MTX + placebo and MTX + adalimumab groups, chi-squared = 0.99. In 90 patients with HBL6months data and 2-year radiographic data, HBL6months was independently associated with ∆TSS after 2 years (β = −0.086 (95% confidence interval = −0.15; −0.025) TSS unit/mg/cm2 increase, p = 0.006) but not with presence of radiographic progression (∆TSS >0) (OR 0.96 (0.92–1.0), p = 0.10). In early RA patients treated with a methotrexate-based treat-to-target strategy, the majority of patients had increased HBL1-year, irrespective of adalimumab; HBL6months was independently associated with ∆TSS after 2 years.

AB - This study aims to investigate 1-year hand bone loss (HBL1-year) in early rheumatoid arthritis (RA) patients treated with a methotrexate (MTX) and intra-articular triamcinolone treat-to-target strategy +/− adalimumab and to determine if HBL6months is associated with radiographic progression after 2 years. In a clinical trial (OPERA) of 180 treatment-naive early RA patients, bone mineral density (BMD) was estimated from hand radiographs with digital X-ray radiogrammetry (DXR) at baseline, after 6 (n = 90) and 12 months (n = 70) of follow-up. Baseline and 2-year radiographs were scored according to the Sharp/van der Heijde method. Baseline characteristics and HBL6months (0–6 months changes in DXR-BMD) were investigated as predictors of structural damage by univariate linear (∆ total Sharp/van der Heijde score (TSS) as dependent variable) and logistic (+/−radiographic progression (∆TSS >0) as dependent variable) regression analyses. Variables with p < 0.10 were included in multivariable models. In 70 patients with available HBL1-year data, HBL1-year was median (interquartile range (IQR)) −1.9 (−3.3; −0.26 mg/cm2) in the MTX + placebo group and −1.8 (−3.6; 0.06) mg/cm2 in the MTX + adalimumab group, p = 0.98, Wilcoxon signed-rank. Increased HBL (compared to general population reference values) was found in 26/37 and 23/33 patients in the MTX + placebo and MTX + adalimumab groups, chi-squared = 0.99. In 90 patients with HBL6months data and 2-year radiographic data, HBL6months was independently associated with ∆TSS after 2 years (β = −0.086 (95% confidence interval = −0.15; −0.025) TSS unit/mg/cm2 increase, p = 0.006) but not with presence of radiographic progression (∆TSS >0) (OR 0.96 (0.92–1.0), p = 0.10). In early RA patients treated with a methotrexate-based treat-to-target strategy, the majority of patients had increased HBL1-year, irrespective of adalimumab; HBL6months was independently associated with ∆TSS after 2 years.

KW - Journal Article

U2 - 10.1007/s10067-016-3489-1

DO - 10.1007/s10067-016-3489-1

M3 - Journal article

C2 - 27921185

SN - 0770-3198

VL - 36

SP - 781

EP - 789

JO - Clinical Rheumatology

JF - Clinical Rheumatology

IS - 4

ER -

Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater